Proteome Profiler Human Phospho-RTK Array Kit

Contains 4 membranes - each spotted in duplicate with 49 different RTK antibodies
Catalog # Availability Size / Price Qty
Detection of Human Receptor Tyrosine Kinase Phosphorylation in KATO-III Cell Line.
2 Images
Product Details
Citations (249)
Supplemental Products
Reviews (7)

Proteome Profiler Human Phospho-RTK Array Kit Summary

Kit Summary

A membrane-based antibody array for the parallel determination of the relative phosphorylation of human receptor tyrosine kinases. Validated for analyte detection in cell lysates.

Troubleshooting Guide

Key Benefits

  • Detects phosphorylation of 49 human receptor tyrosine kinases simultaneously
  • Requires no specialized equipment


Principle of the Assay

The Proteome Profiler Human Phospho-RTK Array Kit is a membrane-based sandwich immunoassay. Capture antibodies spotted in duplicate on nitrocellulose membranes bind to specific target proteins present in the sample (Step 1). Tyrosine phosphorylation of the captured proteins is detected with an HRP-conjugated pan phospho-tyrosine antibody (Step 2) and then visualized using chemiluminescent detection reagents (Step 3). The signal produced is proportional to the amount phosphorylation in the bound analyte.

Why Use an Antibody Array to Detect Receptor Phosphorylation?

Determining the phosphorylation of multiple receptors in a single sample can be expensive, time consuming and can require specialized equipment. Performing multiple immunoprecipitations and Western blots requires time, labor, and reagents. The use of a multiplex antibody array to detect multiple phosphorylations in a single sample can be cost-effective and also save time and sample.

Kit Contents
  • 4 Array Membranes
  • 4-Well Multi-dish
  • Array Buffers
  • Lysis Buffer
  • Wash Buffer
  • Anti-Phospho-Tyrosine-HRP Detection Antibody
  • Chemiluminescent Detection Reagents
  • Transparency Overlay Template
  • Detailed Protocol

For a complete list of the kit contents and necessary materials, please see the Materials Provided/Other Supplies Required sections of the product datasheet.

Stability and Storage

Store the unopened kit at 2 °C to 8 °C. Do not use past kit expiration date.

Simultaneously detect the relative phosphorylation of these RTKs in a single sample
ALK/CD246 EphB4 MuSK
Axl EphB6 PDGF R alpha
DDR1 ErbB2 PDGF R beta
DDR2 ErbB3 c-Ret
Dtk ErbB4 ROR1
EphA1 FGF R2 alpha Ryk
EphA2 FGF R3 SCF R/c-kit
EphA3 FGF R4 Tie-1
EphA4 Flt-3/Flk-2 Tie-2
EphA5 HGF R/c-MET TrkA
EphA6 IGF-I R TrkB
EphA7 Insulin R/CD220 TrkC
EphA10 M-CSF R VEGF R1/Flt-1
EphB2 MSP R/Ron VEGF R3/Flt-4

Assays for Analytes represented in the Proteome Profiler Human Phospho-RTK Array Kit

Analyte Quantikine® ELISA Kits DuoSet® ELISA Development System DuoSet® IC ELISA Development Systems (Total) DuoSet® IC ELISA Development Systems (Phospho) Cell-based ELISA Kits
Axl   DY154 DYC1643    
DDR1     DYC2396 DYC5859  
DDR2     DYC2538 DYC6170  
Dtk   DY859      
EGF R DEGFR0 DY231 DYC1854 DYC1095B  
EphA1     DYC638    
EphA2     DYC3035 DYC4056  
EphA4     DYC3038 DYC4057  
EphB4     DYC3038 DYC4057  
ErbB2   DY1129 DYC1129 DYC1768  
ErbB3   DY348 DYC234 DYC1769 KCB5677
ErbB4     DYC1133 DYC2115
FGF R1       DYC5079  
FGF R2 alpha     DYC665 DYC684  
FGF R3     DYC766 DYC2719  
FGF R4     DYC685 DYC5516  
Flt-3/Flk     DYC912 DYC368  
HGF R/c-MET   DY358 DYC358 DYC2480  
IGF-I R   DY391 DYC305 DYC1770  
Insulin R/CD220     DYC1544 DYC2718  
M-CSF R   DY329 DYC329 DYC3268  
Mer   DY6488 DYC891 DYC2579  
MSP R/Ron     DYC691 DYC1947  
PDGF R alpha     DYC322 DYC2114  
PDGF R beta     DYC385 DYC1767  
SCF R/c-kit DSCR00 DY332 DYC332 DYC3527  
Tie-1   DY5907      
Tie-2 DTE200 DY5159   DCY2720  
TrkA     DYC175 DYC2578  
TrkB     DYC397 DYC688  
TrkC     DYC373    
VEGF R1/Flt-1 DVR100B DY321B   DYC4170  
VEGF R2/KDR DVR200 DY357 DYC1780 DYC1766  
VEGF R3/Flt-4   DY349 DYC3491 DYC2724  


Shipping Conditions
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Product Datasheets

You must select a language.


Scientific Data

Detection of Human Receptor Tyrosine Kinase Phosphorylation in KATO-III Cell Line. KATO-III human gastric carcinoma cells were either untreated or treated with 100 ng/mL rhFGF acidic and 1 μg/mL heparin for 15 minutes. Cells for rhFGF acidic/Heparin treatment either received pre-treatment with the reversible FGF R and VEGF R inhibitor PD 173074 (Tocris, Catalog # 3044), or with the FGF R-specific tyrosine kinase inhibitor SU 5402 (Tocris, Catalog # 3300), or no pre-treatment.

The Human Phospho-RTK Array is specific for ErbB2, ErbB3, and ErbB4 as shown by receptor competition. MDA-MB-453 human breast cancer cells were treated with 100 ng/mL of rhNRG1-beta1/HRG1-beta1 (R&D Systems, Catalog # 396-HB) for 5 minutes. 5 µg of rhErbB2 (R&D Systems, Catalog # 1129-ER), rhErbB3 (R&D Systems, Catalog # 348-RB), or rhErbB4 (R&D Systems, Catalog # 1131-ER) extracellular domains were added to 50 µg of lysate and analyzed using the Human Phospho-RTK Array. Competition of a particular ErbB receptor was observed only with the corresponding recombinant soluble receptor.

Citations for Proteome Profiler Human Phospho-RTK Array Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

249 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors
    Authors: SM Dieter, D Lovecchio, A Pataskar, MK Zowada, PR Körner, A Khalizieva, O van Tellin, D Jäger, H Glimm, R Agami
    Oncogene, 2022;0(0):.  2022
  2. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
    Authors: AJ Weickhardt, DK Lau, M Hodgson-Ga, A Lavis, LJ Jenkins, N Vukelic, P Ioannidis, IY Luk, JM Mariadason
    BMC Cancer, 2022;22(1):478.  2022
  3. Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor
    Authors: J Zhi, J Yi, X Hou, W Wang, W Yang, L Hu, J Huang, S Guo, X Ruan, M Gao, X Zheng
    American journal of cancer research, 2022;12(1):247-264.  2022
  4. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma
    Authors: L Scherschin, M Prem, I Kremenetsk, I Tinhofer, P Vajkoczy, AG Karbe, JS Onken
    International Journal of Molecular Sciences, 2022;23(2):.  2022
  5. Stem Cells From Human Exfoliated Deciduous Teeth-Conditioned Medium (SHED-CM) is a Promising Treatment for Amyotrophic Lateral Sclerosis
    Authors: T Ueda, T Ito, M Inden, H Kurita, A Yamamoto, I Hozumi
    Frontiers in Pharmacology, 2022;13(0):805379.  2022
  6. EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli
    Authors: S Song, Z Yu, Y You, C Liu, X Xie, H Lv, F Xiao, Q Zhu, C Qin
    Cell Death & Disease, 2022;13(4):351.  2022
  7. Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo
    Authors: C Vannas, L Andersson, S Dolatabadi, P Ranji, M Lindén, E Jonasson, A Ståhlberg, H Fagman, P Åman
    Biomedicines, 2022;10(3):.  2022
  8. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion
    Authors: C Gaiteiro, J Soares, M Relvas-San, A Peixoto, D Ferreira, P Paulo, A Brandão, E Fernandes, R Azevedo, C Palmeira, R Freitas, A Miranda, H Osório, J Prieto, L Lima, AMN Silva, LL Santos, JA Ferreira
    Theranostics, 2022;12(7):3150-3177.  2022
  9. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy
    Authors: MB Ryan, O Coker, A Sorokin, K Fella, H Barnes, E Wong, P Kanikarla, F Gao, Y Zhang, L Zhou, S Kopetz, RB Corcoran
    Cell Reports, 2022;39(12):110993.  2022
  10. Thiosemicarbazones and selected tyrosine kinase inhibitors synergize in pediatric solid tumors: NDRG1 upregulation and impaired prosurvival signaling in neuroblastoma cells
    Authors: M Krchniakov, S Paukovceko, P Chlapek, J Neradil, J Skoda, R Veselska
    Frontiers in Pharmacology, 2022;13(0):976955.  2022
  11. Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors
    Authors: Y Kobayashi, GR Oxnard, EF Cohen, NR Mahadevan, JV Alessi, YP Hung, AA Bertram, DE Heppner, MF Ribeiro, KP Sacardo, R Saddi, MP Macedo, RB Blasco, J Li, KJ Kurppa, T Nguyen, E Voligny, G Ananda, R Chiarle, A Katz, MY Tolstoruko, LM Sholl, PA Jänne
    Nature Communications, 2022;13(1):5614.  2022
  12. Regulation of CCL2 by EZH2 affects tumor-associated macrophages polarization and infiltration in breast cancer
    Authors: YF Wang, L Yu, ZL Hu, YF Fang, YY Shen, MF Song, Y Chen
    Cell Death & Disease, 2022;13(8):748.  2022
  13. Glycosyltransferases EXTL2 and EXTL3 cellular balance dictates Heparan Sulfate biosynthesis and shapes gastric cancer cell motility and invasion
    Authors: C Marques, J Poças, C Gomes, I Faria-Ramo, CA Reis, RR Vivès, A Magalhães
    The Journal of Biological Chemistry, 2022;0(0):102546.  2022
  14. ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT)
    Authors: JD Choi, TJ Kim, BC Jeong, HG Jeon, SS Jeon, MY Kang, SY Yeom, SI Seo
    Scientific Reports, 2021;11(1):21984.  2021
  15. DNA damage response- and JAK-dependent regulation of PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) cells exposed to 5-fluorouracil (5-FU)
    Authors: C Lailler, M Lamuraglia, F Racine, C Louandre, C Godin, B Chauffert, A Galmiche, Z Saidak
    Translational Oncology, 2021;14(8):101110.  2021
  16. Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines
    Authors: DI Korec, DS Louke, JT Breitbach, JA Geisler, BD Husbands, JM Fenger
    Bmc Veterinary Research, 2021;17(1):320.  2021
  17. Effect of cyclic mechanical loading on immunoinflammatory microenvironment in biofabricating hydroxyapatite scaffold for bone regeneration
    Authors: P Zhang, X Liu, P Guo, X Li, Z He, Z Li, MJ Stoddart, S Grad, W Tian, D Chen, X Zou, Z Zhou, S Liu
    Bioactive materials, 2021;6(10):3097-3108.  2021
  18. Oral submucous fibrosis stimulates invasion and epithelial-mesenchymal transition in oral squamous cell carcinoma by activating MMP-2 and IGF-IR
    Authors: PN Chen, CW Lin, SF Yang, YC Chang
    Journal of Cellular and Molecular Medicine, 2021;0(0):.  2021
  19. Identification of Phospho-Tyrosine Targets as a Strategy for the Treatment of Esophageal Adenocarcinoma Cells
    Authors: J Lee, R Chen, T Mohanakuma, R Bremner, S Mittal, TP Fleming
    OncoTargets and Therapy, 2021;14(0):3813-3820.  2021
  20. Galectin?9 suppresses the tumor growth of colon cancer in�vitro and in�vivo
    Authors: A Morishita, K Nomura, J Tani, K Fujita, H Iwama, K Takuma, M Nakahara, T Tadokoro, K Oura, T Chiyo, S Fujihara, T Niki, M Hirashima, A Nishiyama, T Himoto, T Masaki
    Oncology reports, 2021;45(6):.  2021
  21. NOTCH1 signaling promotes protein stability of HER3 through the AKT pathway in squamous cell carcinoma of head and neck
    Authors: YP Wang, IJ Liu, KC Chen, HC Wu
    Oncogenesis, 2021;10(8):59.  2021
  22. Identification of a Resistance Mechanism to IGF-IR Targeting in Human Triple Negative MDA-MB-231 Breast Cancer Cells
    Authors: J Tsui, S Qi, S Perrino, M Leibovitch, P Brodt
    Biomolecules, 2021;11(4):.  2021
  23. IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
    Authors: H Patel, R Mishra, N Yacoub, S Alanazi, MK Kilroy, JT Garrett
    Cancers, 2021;13(22):.  2021
  24. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation
    Authors: HH Lee, YN Wang, WH Yang, W Xia, Y Wei, LC Chan, YH Wang, Z Jiang, S Xu, J Yao, Y Qiu, YH Hsu, WL Hwang, M Yan, JH Cha, JL Hsu, J Shen, Y Ye, X Wu, MF Hou, LM Tseng, SC Wang, MR Pan, CH Yang, YL Wang, H Yamaguchi, D Pang, GN Hortobagyi, D Yu, MC Hung
    Nature Communications, 2021;12(1):2788.  2021
  25. Self-assembly of differentiated progenitor cells facilitates spheroid human skin organoid formation and planar skin regeneration
    Authors: P Ebner-Peki, L Krisch, M Wolf, S Hochmann, A Hoog, B Vári, K Muigg, R Poupardin, C Scharler, S Schmidhube, E Russe, H Stachelsch, A Schneeberg, K Schallmose, D Strunk
    Theranostics, 2021;11(17):8430-8447.  2021
  26. Identification of Nucleolin as a Novel AEG-1-Interacting Protein in Breast Cancer via Interactome Profiling
    Authors: SJ Lee, KM Choi, G Bang, SG Park, EB Kim, JW Choi, YH Chung, J Kim, SG Lee, E Kim, JY Kim
    Cancers, 2021;13(11):.  2021
  27. Interaction between SCP3 and JAB1 Confers Cancer Therapeutic Resistance and Stem-like Properties through EGF Expression
    Authors: SJ Oh, KH Noh, KH Song, TW Kim
    International Journal of Molecular Sciences, 2021;22(16):.  2021
  28. Novel patient-derived models of DSRCT enable validation of ERBB signaling as a potential therapeutic vulnerability
    Authors: RS Smith, I Odintsov, Z Liu, AJ Lui, T Hayashi, M Vojnic, Y Suehara, L Delasos, MS Mattar, J Hmeljak, HA Ramirez, M Shaw, G Bui, AB Hartono, E Gladstone, S Kunte, H Magnan, I Khodos, E De Stanchi, MP La Quaglia, J Yao, M Laé, SB Lee, L Spraggon, CA Pratilas, M Ladanyi, R Somwar
    Disease Models & Mechanisms, 2021;0(0):.  2021
  29. Cabozantinib Is Effective in Melanoma Brain Metastasis Cell Lines and Affects Key Signaling Pathways
    Authors: TA Mannsåker, T Hoang, SN Aasen, OV Bjørnstad, H Parajuli, T Sundstrøm, FA Thorsen
    International Journal of Molecular Sciences, 2021;22(22):.  2021
  30. Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1alpha/TGF-alpha expression
    Authors: K Nishii, K Ohashi, H Watanabe, G Makimoto, T Nakasuka, H Higo, K Ninomiya, Y Kato, T Kubo, K Rai, E Ichihara, K Hotta, M Tabata, Y Maeda, K Kiura
    Oncology Letters, 2021;22(3):639.  2021
  31. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation
    Authors: AC Harttrampf, MEM da Costa, A Renoult, E Daudigeos-, B Geoerger
    BMC Cancer, 2021;21(1):833.  2021
  32. LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance
    Authors: O Billing, Y Holmgren, D Nosek, H Hedman, O Hemmingsso
    Oncogene, 2021;0(0):.  2021
  33. The Cardenolide Glycoside Acovenoside A Interferes with Epidermal Growth Factor Receptor Trafficking in Non-Small Cell Lung Cancer Cells
    Authors: S Hafner, M Schmiech, SJ Lang
    Frontiers in Pharmacology, 2021;12(0):611657.  2021
  34. Three newly established immortalized mesothelial cell lines exhibit morphological phenotypes corresponding to malignant mesothelioma epithelioid, intermediate, and sarcomatoid types, respectively
    Authors: T Sato, H Nakanishi, K Akao, M Okuda, S Mukai, T Kiyono, Y Sekido
    Cancer Cell International, 2021;21(1):546.  2021
  35. New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRbeta Signaling
    Authors: M Mahdal, J Neradil, P Mudry, S Paukovceko, I Staniczkov, J Urban, P Macsek, L Pazourek, T Tomas, R Veselska
    Cancers, 2021;13(14):.  2021
  36. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells
    Authors: N Singh, NV Frey, B Engels, DM Barrett, O Shestova, P Ravikumar, KD Cummins, YG Lee, R Pajarillo, I Chun, A Shyu, SL Highfill, A Price, L Zhao, L Peng, B Granda, M Ramones, XM Lu, DA Christian, J Perazzelli, SF Lacey, NH Roy, JK Burkhardt, F Colomb, M Damra, M Abdel-Mohs, T Liu, D Liu, DM Standley, RM Young, JL Brogdon, SA Grupp, CH June, SL Maude, S Gill, M Ruella
    Nature Medicine, 2021;0(0):.  2021
  37. Chondroitin sulfate synthase 1 enhances proliferation of glioblastoma by modulating PDGFRA stability
    Authors: WC Liao, CK Liao, TJ Tseng, YJ Ho, YR Chen, KH Lin, TJ Lai, CT Lan, KC Wei, CH Liu
    Oncogenesis, 2020;9(2):9.  2020
  38. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms
    Authors: N Yanagitani, K Uchibori, S Koike, M Tsukahara, S Kitazono, T Yoshizawa, A Horiike, F Ohyanagi, Y Tambo, S Nishikawa, N Fujita, R Katayama, M Nishio
    Cancer Sci., 2020;111(3):932-939.  2020
  39. Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma
    Authors: Z Areeb, SF Stuart, AJ West, J Gomez, HPT Nguyen, L Paradiso, A Zulkifli, J Jones, AH Kaye, AP Morokoff, RB Luwor
    Sci Rep, 2020;10(1):17768.  2020
  40. Syndecan-1 Promotes Hepatocyte-Like Differentiation of Hepatoma Cells Targeting Ets-1 and AP-1
    Authors: P Hollósi, L Váncza, K Karászi, K Dobos, B Péterfia, E Tátrai, P Tátrai, T Szarvas, S Paku, L Szilák, I Kovalszky
    Biomolecules, 2020;10(10):.  2020
  41. Extracellular SQSTM1 mediates bacterial septic death in mice through insulin receptor signalling
    Authors: B Zhou, J Liu, L Zeng, S Zhu, H Wang, TR Billiar, G Kroemer, DJ Klionsky, HJ Zeh, J Jiang, D Tang, R Kang
    Nat Microbiol, 2020;0(0):.  2020
  42. Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines
    Authors: M Fuentes-Ba, MP Ventero, JA Encinar, P García-Mor, M Poveda-Del, E Pérez-Vale, VM Barberá, J Gallego-Pl, Á Rodríguez-, J Martín-Nie, M Saceda
    Cancers, 2020;12(12):.  2020
  43. MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies
    Authors: S Roy, A Laroche-Cl, S Verbeke, MA Derieppe, A Italiano
    Cancers (Basel), 2020;12(8):.  2020
  44. Sarmentosamide, an Anti-Aging Compound from a Marine-Derived Streptomyces sp. APmarine042
    Authors: ES Lee, EY Lee, J Yoon, A Hong, SJ Nam, J Ko
    Mar Drugs, 2020;18(9):.  2020
  45. Differential Dependency of Human Pancreatic Cancer Cells on Targeting PTEN via PLK 1 Expression
    Authors: J Lee, J Lee, W Sim, JH Kim
    Cancers (Basel), 2020;12(2):.  2020
  46. Serial Xenotransplantation in NSG Mice Promotes a Hybrid Epithelial/Mesenchymal Gene Expression Signature and Stemness in Rhabdomyosarcoma Cells
    Authors: J Skoda, J Neradil, I Staniczkov, A Nunukova, P Macsek, K Borankova, V Dobrotkova, P Nemec, J Sterba, R Veselska
    Cancers (Basel), 2020;12(1):.  2020
  47. STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations
    Authors: J Kim, D Novak, C Sachpekidi, J Utikal, L Larribère
    Cancers (Basel), 2020;12(1):.  2020
  48. ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL
    Authors: S Pietrobono, G Anichini, C Sala, F Manetti, LL Almada, S Pepe, RM Carr, BD Paradise, JN Sarkaria, JI Davila, L Tofani, I Battisti, G Arrigoni, L Ying, C Zhang, H Li, A Meves, ME Fernandez-, B Stecca
    Nat Commun, 2020;11(1):5865.  2020
  49. IGF2 autocrine-mediated IGF1R activation is a clinically relevant mechanism of osimertinib resistance in lung cancer
    Authors: T Manabe, H Yasuda, H Terai, H Kagiwada, J Hamamoto, T Ebisudani, K Kobayashi, K Masuzawa, S Ikemura, I Kawada, Y Hayashi, K Fukui, K Horimoto, K Fukunaga, K Soejima
    Mol. Cancer Res., 2020;0(0):.  2020
  50. CXCL14 Maintains hESC Self-Renewal through Binding to IGF-1R and Activation of the IGF-1R Pathway
    Authors: CL Cheng, SC Yang, CY Lai, CK Wang, CF Chang, CY Lin, WJ Chen, PY Lin, HC Wu, N Ma, FL Lu, J Lu
    Cells, 2020;9(7):.  2020
  51. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer
    Authors: PC Lee, ST Chen, TC Kuo, TC Lin, MC Lin, J Huang, JS Hung, CL Hsu, HF Juan, PH Lee, MC Huang
    Oncogene, 2020;0(0):.  2020
  52. Comprehensive Biology and Genetics Compendium of Wilms Tumor Cell Lines with Different WT1 Mutations
    Authors: B Royer-Poko, MA Busch, S Tenbusch, M Schmidt, M Beier, AD Woods, H Thiele, J Mora
    Cancers, 2020;13(1):.  2020
  53. LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells
    Authors: S Kim, H Cho, SO Hong, SJ Oh, HJ Lee, E Cho, SR Woo, JS Song, JY Chung, SW Son, SM Yoon, YM Jeon, S Jeon, C Yee, KM Lee, SM Hewitt, JH Kim, KH Song, TW Kim
    Autophagy, 2020;0(0):1-20.  2020
  54. MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies
    Authors: S Roy, A Laroche-Cl, S Verbeke, MA Derieppe, A Italiano
    Cancers (Basel), 2020;12(8):.  2020
  55. HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma
    Authors: L Hüser, MM Kokkalenio, K Granados, J Dworacek, A Federico, M Vierthaler, D Novak, I Arkhypov, T Hielscher, V Umansky, P Altevogt, J Utikal
    Cancers, 2020;12(12):.  2020
  56. EPHA2 feedback activation limits the response to PDEdelta inhibition in KRAS-dependent cancer cells
    Authors: YH Chen, H Lv, N Shen, XM Wang, S Tang, B Xiong, J Ding, MY Geng, M Huang
    Acta Pharmacol. Sin., 2020;41(2):270-277.  2020
  57. Intrinsic Resistance to MEK Inhibition Through BET Protein Mediated Kinome Reprogramming in NF1-deficient Ovarian Cancer
    Authors: AM Kurimchak, C Shelton, C Herrera-Mo, KE Duncan, J Chernoff, JS Duncan
    Mol. Cancer Res., 2019;0(0):.  2019
  58. Telmisartan Inhibits Cell Proliferation and Tumor Growth of Esophageal Squamous Cell Carcinoma by Inducing S-Phase Arrest In Vitro and In Vivo
    Authors: T Matsui, T Chiyo, H Kobara, S Fujihara, K Fujita, D Namima, M Nakahara, N Kobayashi, N Nishiyama, T Yachida, A Morishita, H Iwama, T Masaki
    Int J Mol Sci, 2019;20(13):.  2019
  59. Epigenomic Profiling Discovers Trans-lineage SOX2 Partnerships Driving Tumor Heterogeneity in Lung Squamous Cell Carcinoma
    Authors: T Sato, S Yoo, R Kong, A Sinha, P Chandraman, A Patel, M Fridrikh, O Nagano, T Masuko, MB Beasley, CA Powell, J Zhu, H Watanabe
    Cancer Res., 2019;79(24):6084-6100.  2019
  60. Mechanisms of entrectinib resistance in a neuroblastoma xenograft model
    Authors: SP MacFarland, K Naraparaju, R Iyer, P Guan, V Kolla, Y Hu, K Tan, GM Brodeur
    Mol. Cancer Ther., 2019;0(0):.  2019
  61. An investigation of the equine epidermal growth factor system during hyperinsulinemic laminitis
    Authors: MA de Laat, RJ Spence, MN Sillence, CC Pollitt
    PLoS ONE, 2019;14(12):e0225843.  2019
  62. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
    Authors: R Sulahian, JJ Kwon, KH Walsh, E Pailler, TL Bosse, M Thaker, D Almanza, JM Dempster, J Pan, F Piccioni, N Dumont, A Gonzalez, J Rennhack, B Nabet, JA Bachman, A Goodale, Y Lee, M Bagul, R Liao, A Navarro, TL Yuan, RWS Ng, S Raghavan, NS Gray, A Tsherniak, F Vazquez, DE Root, AJ Firestone, J Settleman, WC Hahn, AJ Aguirre
    Cell Rep, 2019;29(1):118-134.e8.  2019
  63. 2-Deoxy-d-Glucose-Induced Metabolic Alteration in Human Oral Squamous SCC15 Cells: Involvement of N-Glycosylation of Axl and Met
    Authors: N Lee, WJ Jang, JH Seo, S Lee, CH Jeong
    Metabolites, 2019;9(9):.  2019
  64. Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach
    Authors: Z Xiao, B Sperl, S Gärtner, T Nedelko, E Stacher-Pr, A Ullrich, PG Knyazev
    Oncotarget, 2019;10(26):2546-2560.  2019
  65. A Role of Agrin in Maintaining the Stability of Vascular Endothelial Growth Factor Receptor-2 during Tumor Angiogenesis
    Authors: K Njah, S Chakrabort, B Qiu, S Arumugam, A Raju, AV Pobbati, M Lakshmanan, V Tergaonkar, G Thibault, X Wang, W Hong
    Cell Rep, 2019;28(4):949-965.e7.  2019
  66. Establishment of a novel human CIC-DUX4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs
    Authors: S Nakai, S Yamada, H Outani, T Nakai, N Yasuda, H Mae, Y Imura, T Wakamatsu, H Tamiya, T Tanaka, K Hamada, A Tani, A Myoui, N Araki, T Ueda, H Yoshikawa, S Takenaka, N Naka
    Sci Rep, 2019;9(1):15812.  2019
  67. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors
    Authors: TA Ahmed, C Adamopoulo, Z Karoulia, X Wu, R Sachidanan, SA Aaronson, PI Poulikakos
    Cell Rep, 2019;26(1):65-78.e5.  2019
  68. Modeling Patient-Derived Glioblastoma with Cerebral Organoids
    Authors: A Linkous, D Balamatsia, M Snuderl, L Edwards, K Miyaguchi, T Milner, B Reich, L Cohen-Goul, A Storaska, Y Nakayama, E Schenkein, R Singhania, S Cirigliano, T Magdeldin, Y Lin, G Nanjangud, K Chadalavad, D Pisapia, C Liston, HA Fine
    Cell Rep, 2019;26(12):3203-3211.e5.  2019
  69. Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer
    Authors: R Graves-Dea, G Bogatcheva, S Rehman, Y Lu, JN Higginboth, B Singh
    Oncotarget, 2019;10(13):1320-1333.  2019
  70. A multi-targeted probe-based strategy to identify signaling vulnerabilities in cancers
    Authors: S Rao, G Du, M Hafner, K Subramania, PK Sorger, NS Gray
    J. Biol. Chem., 2019;0(0):.  2019
  71. Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status
    Authors: K Fukuda, S Takeuchi, S Arai, R Katayama, S Nanjo, A Tanimoto, A Nishiyama, T Nakagawa, H Taniguchi, T Suzuki, T Yamada, H Nishihara, H Ninomiya, Y Ishikawa, S Baba, K Takeuchi, A Horiike, N Yanagitani, M Nishio, S Yano
    Cancer Res., 2019;0(0):.  2019
  72. Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis
    Authors: L He, L Gao, C Shay, L Lang, F Lv, Y Teng
    J. Exp. Clin. Cancer Res., 2019;38(1):84.  2019
  73. Differential anti-tumour effects of MTH1 inhibitors in patient-derived 3D colorectal cancer cultures
    Authors: LM van der Wa, J Laoukili, JMJ Jongen, DA Raats, IHM Borel Rink, O Kranenburg
    Sci Rep, 2019;9(1):819.  2019
  74. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas
    Authors: Q Zhang, JH Liu, JL Liu, CT Qi, L Yan, Y Chen, Q Yu
    BMC Cancer, 2019;19(1):1044.  2019
  75. Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors
    Authors: MT Kuo, Y Long, WB Tsai, YY Li, HHW Chen, LG Feun, N Savaraj
    Transl Oncol, 2019;13(2):355-364.  2019
  76. Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer
    Authors: SH Park, MJ Jo, BR Kim, YA Jeong, YJ Na, JL Kim, S Jeong, HK Yun, DY Kim, BG Kim, SH Kang, SC Oh, DH Lee
    Theranostics, 2019;9(8):2235-2251.  2019
  77. EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming
    Authors: F Meng, L Wu, L Dong, AV Mitchell, C James Bloc, J Liu, H Zhang, Q Lu, WM Song, B Zhang, W Chen, J Hu, J Wang, Q Yang, M Hüttemann, G Wu
    Nat Commun, 2019;10(1):5033.  2019
  78. Tumor-specific inhibitory action of decorin on different hepatoma cell lines
    Authors: Z Horváth, A Reszegi, L Szilák, T Dankó, I Kovalszky, K Baghy
    Cell. Signal., 2019;62(0):109354.  2019
  79. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo
    Authors: S Boichuk, A Galembikov, P Dunaev, E Micheeva, E Valeeva, M Novikova, N Khromova, P Kopnin
    Molecules, 2018;23(10):.  2018
  80. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers
    Authors: H Kotani, Y Adachi, H Kitai, S Tomida, H Bando, AC Faber, T Yoshino, DC Voon, S Yano, H Ebi
    Oncogene, 2018;0(0):.  2018
  81. A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
    Authors: AH Daneshmane, M Hojjat-Far, A Ghaderi, A Moshfegh, L Hansson, J Schultz, J Vågberg, S Byström, E Olsson, T Olin, A Österborg, H Mellstedt
    PLoS ONE, 2018;13(6):e0198038.  2018
  82. Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs
    Authors: B Haas, V Klinger, C Keksel, V Bonigut, D Kiefer, J Caspers, J Walther, M Wos-Magang, S Weickhardt, G Röhn, M Timmer, R Frötschl, N Eckstein
    Cancer Cell Int., 2018;18(0):69.  2018
  83. MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
    Authors: K Ninomiya, K Ohashi, G Makimoto, S Tomida, H Higo, H Kayatani, T Ninomiya, T Kubo, E Ichihara, K Hotta, M Tabata, Y Maeda, K Kiura
    Sci Rep, 2018;8(1):1955.  2018
  84. Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB3
    Authors: WJ Jang, SK Jung, TTL Vo, CH Jeong
    J. Cell. Mol. Med., 2018;0(0):.  2018
  85. TROP-2 exhibits tumor suppressive functions in cervical cancer by dual inhibition of IGF-1R and ALK signaling
    Authors: STK Sin, Y Li, M Liu, S Ma, XY Guan
    Gynecol. Oncol., 2018;0(0):.  2018
  86. Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma
    Authors: F Mao, C Holmlund, M Faraz, W Wang, T Bergenheim, S Kvarnbrink, M Johansson, R Henriksson, H Hedman
    Oncogenesis, 2018;7(2):13.  2018
  87. Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a PDGFRB Mutation Associated with Infantile Myofibromatosis
    Authors: M Sramek, J Neradil, P Macigova, P Mudry, K Polaskova, O Slaby, H Noskova, J Sterba, R Veselska
    Int J Mol Sci, 2018;19(9):.  2018
  88. Tumour-vasculature development via endothelial-to-mesenchymal transition after radiotherapy controls CD44v6+ cancer cell and macrophage polarization
    Authors: SH Choi, AR Kim, JK Nam, JM Kim, JY Kim, HR Seo, HJ Lee, J Cho, YJ Lee
    Nat Commun, 2018;9(1):5108.  2018
  89. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway
    Authors: ST Chen, TC Kuo, YY Liao, MC Lin, YW Tien, MC Huang
    Oncogene, 2018;0(0):.  2018
  90. Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma
    Authors: U Painuly, V Ramakrishn, T Kimlinger, L Wellik, J Haug, W Gonsalves, L Bi, Z Huang, SV Rajkumar, S Kumar
    Oncotarget, 2018;9(77):34582-34594.  2018
  91. Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target
    Authors: J Heliste, A Jokilammi, I Paatero, D Chakrobort, C Stark, T Savunen, M Laaksonen, K Elenius
    BMC Cardiovasc Disord, 2018;18(1):196.  2018
  92. HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation
    Authors: S Sun, Y Zhang, J Zheng, B Duan, J Cui, Y Chen, W Deng, B Ye, L Liu, Y Chen, J Du, L Gu
    Cell Death Dis, 2018;9(9):929.  2018
  93. Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation
    Authors: AR Virzì, A Gentile, S Benvenuti, PM Comoglio
    Proc. Natl. Acad. Sci. U.S.A., 2018;0(0):.  2018
  94. Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-?/STAT3 Pathway
    Authors: Z Fang, KH Jung, HH Yan, SJ Kim, M Rumman, JH Park, B Han, JE Lee, YW Kang, JH Lim, SS Hong
    Cell. Physiol. Biochem., 2018;47(5):1751-1768.  2018
  95. The secretome engages STAT3 to favor a cytokine-rich microenvironment in mediating acquired resistance to FGFR inhibitors
    Authors: X Wang, J Ai, H Liu, X Peng, H Chen, Y Chen, Y Su, A Shen, X Huang, J Ding, M Geng
    Mol. Cancer Ther., 2018;0(0):.  2018
  96. BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC
    Authors: B Leonard, TM Brand, RA O'Keefe, E Lee, Y Zang, JD Kemmer, H Li, JR Grandis, NE Bhola
    Cancer Res., 2018;0(0):.  2018
  97. Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-Tissue Sarcoma: Potential Therapeutic implication for Synovial Sarcoma
    Authors: PP Patwardhan, E Musi, GK Schwartz
    Mol. Cancer Ther., 2018;0(0):.  2018
  98. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines
    Authors: R Herr, S Halbach, M Heizmann, H Busch, M Boerries, T Brummer
    Oncogene, 2018;0(0):.  2018
  99. YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics
    Authors: PD Fan, G Narzisi, AD Jayaprakas, E Venturini, N Robine, P Smibert, S Germer, HA Yu, EJ Jordan, PK Paik, YY Janjigian, JE Chaft, L Wang, AA Jungbluth, S Middha, L Spraggon, H Qiao, CM Lovly, MG Kris, GJ Riely, K Politi, H Varmus, M Ladanyi
    Proc. Natl. Acad. Sci. U.S.A., 2018;115(26):E6030-E6038.  2018
  100. Identification of FDA-approved oncology drugs with selective potency in high-risk childhood ependymoma
    Authors: AM Donson, V Amani, EA Warner, AM Griesinger, DA Witt, JM Mulcahy Le, LM Hoffman, TC Hankinson, MH Handler, R Vibhakar, K Dorris, NK Foreman
    Mol. Cancer Ther., 2018;0(0):.  2018
  101. LAMB3 mediates metastatic tumor behavior in papillary thyroid cancer by regulating c-MET/Akt signals
    Authors: SN Jung, HS Lim, L Liu, JW Chang, YC Lim, KS Rha, BS Koo
    Sci Rep, 2018;8(1):2718.  2018
  102. Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target
    Authors: E Yángüez, A Hunziker, MP Dobay, S Yildiz, S Schading, E Elshina, U Karakus, P Gehrig, J Grossmann, R Dijkman, M Schmolke, S Stertz
    Nat Commun, 2018;9(1):3679.  2018
  103. Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3
    Authors: SA Greenall, J Donoghue, TG Johns, TE Adams
    Transl Oncol, 2018;11(4):971-978.  2018
  104. Mucin 2 silencing promotes colon cancer metastasis through interleukin-6 signaling
    Authors: HP Hsu, MD Lai, JC Lee, MC Yen, TY Weng, WC Chen, JH Fang, YL Chen
    Sci Rep, 2017;7(1):5823.  2017
  105. Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer
    Authors: C Li, B Singh, R Graves-Dea, H Ma, A Starchenko, WH Fry, Y Lu, Y Wang, G Bogatcheva, MP Khan, GL Milne, S Zhao, GD Ayers, N Li, H Hu, MK Washington, TJ Yeatman, OG McDonald, Q Liu, RJ Coffey
    Proc. Natl. Acad. Sci. U.S.A, 2017;0(0):.  2017
  106. Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest
    Authors: K Oura, T Tadokoro, S Fujihara, A Morishita, T Chiyo, E Samukawa, Y Yamana, K Fujita, T Sakamoto, T Nomura, H Yoneyama, H Kobara, H Mori, H Iwama, K Okano, Y Suzuki, T Masaki
    Oncol. Rep., 2017;38(5):2825-2835.  2017
  107. Osteoblastic heparan sulfate glycosaminoglycans control bone remodeling by regulating Wnt signaling and the crosstalk between bone surface and marrow cells
    Authors: R Mansouri, Y Jouan, E Hay, C Blin-Wakka, M Frain, A Ostertag, C Le Henaff, C Marty, V Geoffroy, PJ Marie, M Cohen-Sola, D Modrowski
    Cell Death Dis, 2017;8(6):e2902.  2017
  108. Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications
    Authors: SS Yadav, J Li, JA Stockert, B Herzog, J O'Connor, L Garzon-Man, R Parsons, AK Tewari, KK Yadav
    Transl Oncol, 2017;10(3):357-366.  2017
  109. Amplification of EGFR wild type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors
    Authors: S Nukaga, H Yasuda, K Tsuchihara, J Hamamoto, K Masuzawa, I Kawada, K Naoki, S Matsumoto, S Mimaki, S Ikemura, K Goto, T Betsuyaku, K Soejima
    Cancer Res, 2017;0(0):.  2017
  110. Ectodomain Shedding of the Cell Adhesion Molecule Nectin-4 in Ovarian Cancer is Mediated by ADAM10 and ADAM17
    Authors: PC Buchanan, KL Boylan, B Walcheck, R Heinze, MA Geller, PA Argenta, AP Skubitz
    J. Biol. Chem, 2017;0(0):.  2017
  111. Insulin-like Growth Factor-1 signalling is essential for Mitochondrial Biogenesis and Mitophagy in cancer cells
    Authors: A Lyons, M Coleman, S Riis, C Favre, CH O'Flanagan, AV Zhdanov, DB Papkovsky, SD Hursting, R O'Connor
    J. Biol. Chem., 2017;0(0):.  2017
  112. BCL6 promotes glioma and serves as a therapeutic target
    Authors: L Xu, Y Chen, M Dutra-Clar, A Mayakonda, M Hazawa, SE Savinoff, N Doan, JW Said, WH Yong, A Watkins, H Yang, LW Ding, YY Jiang, JW Tyner, J Ching, JP Kovalik, V Madan, SL Chan, M Müschen, JJ Breunig, DC Lin, HP Koeffler
    Proc. Natl. Acad. Sci. U.S.A, 2017;0(0):.  2017
  113. Piperlongumine downregulates the expression of HER family in breast cancer cells
    Authors: HO Jin, JA Park, HA Kim, YH Chang, YJ Hong, IC Park, JK Lee
    Biochem. Biophys. Res. Commun., 2017;0(0):.  2017
  114. mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism
    Authors: A Lampada, J O'Prey, G Szabadkai, KM Ryan, D Hochhauser, P Salomoni
    Cell Death Differ., 2017;0(0):.  2017
  115. High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors
    Authors: C Chauvin, A Leruste, A Tauziede-E, M Andrianter, D Surdez, A Lescure, ZY Han, E Anthony, W Richer, S Baulande, M Bohec, S Zaidi, MM Aynaud, L Maillot, J Masliah-Pl, S Cairo, S Roman-Roma, O Delattre, E Del Nery, F Bourdeaut
    Cell Rep, 2017;21(7):1737-1745.  2017
  116. Mechanisms of primary drug resistance in FGFR1 amplified lung cancer
    Authors: F Malchers, MS Ercanoglu, D Schütte, R Castiglion, V Tischler, S Michels, I Dahmen, J Brägelmann, R Menon, JM Heuckmann, J George, S Ansén, ML Sos, A Soltermann, M Peifer, J Wolf, R Büttner, RK Thomas
    Clin. Cancer Res., 2017;0(0):.  2017
  117. Protein C receptor stimulates multiple signaling pathways in breast cancer cells
    Authors: D Wang, C Liu, J Wang, Y Jia, X Hu, H Jiang, ZM Shao, YA Zeng
    J. Biol. Chem., 2017;0(0):.  2017
  118. EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming
    Authors: R Adelaiye-O, J Budka, NP Damayanti, J Arrington, MW Ferris, CC Hsu, S Chintala, AR Orillion, KM Miles, L Shen, M Elbanna, E Ciamporcer, S Arisa, P Pettazzoni, GF Draetta, M Seshadri, BA Hancock, M Radovich, J Kota, M Buck, H Keilhack, BP McCarthy, SA Persohn, PR Territo, Y Zang, J Irudayaraj, AW Tao, P Hollenhors, R Pili
    Cancer Res., 2017;0(0):.  2017
  119. Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS
    Authors: E Saintas, L Abrahams, GT Ahmad, AM Ajakaiye, AS AlHumaidi, C Ashmore-Ha, I Clark, UK Dura, CN Fixmer, C Ike-Morris, M Mato Prado, D Mccullough, S Mishra, KM Schöler, H Timur, MD Williamson, M Alatsatian, B Bahsoun, E Blackburn, CE Hogwood, PE Lithgow, M Rowe, L Yiangou, F Rothweiler, J Cinatl, R Zehner, AJ Baines, MD Garrett, CW Gourlay, DK Griffin, WJ Gullick, E Hargreaves, MJ Howard, DR Lloyd, JS Rossman, CM Smales, AD Tsaousis, T von der Ha, MN Wass, M Michaelis
    PLoS ONE, 2017;12(2):e0172140.  2017
  120. Altered Met Receptor Phosphorylation and LRP1 Mediated Uptake in Cells Lacking Carbohydrate-Dependent Lysosomal Targeting
    Authors: M Aarnio-Pet, P Zhao, SH Yu, C Christian, H Flanagan-S, L Wells, R Steet
    J. Biol. Chem., 2017;0(0):.  2017
  121. MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer
    Authors: S Nanjo, S Arai, W Wang, S Takeuchi, T Yamada, A Hata, N Katakami, Y Okada, S Yano
    Mol. Cancer Ther, 2017;0(0):.  2017
  122. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis
    Authors: K Noh, LS Mangala, HD Han, N Zhang, S Pradeep, SY Wu, S Ma, E Mora, R Rupaimoole, D Jiang, Y Wen, MMK Shahzad, Y Lyons, M Cho, W Hu, AS Nagaraja, M Haemmerle, CSL Mak, X Chen, KM Gharpure, H Deng, W Xiong, CV Kingsley, J Liu, N Jennings, MJ Birrer, RR Bouchard, G Lopez-Bere, RL Coleman, Z An, AK Sood
    Cell Rep, 2017;21(10):2785-2795.  2017
  123. In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines
    Authors: L Klameth, B Rath, G Hamilton
    J Cancer, 2017;8(10):1733-1743.  2017
  124. Overcoming resistance to cetuximab with honokiol, a small-molecule polyphenol
    Authors: HE Pearson, M Iida, RA Orbuch, NK McDaniel, KP Nickel, RJ Kimple, J Arbiser, DL Wheeler
    Mol. Cancer Ther., 2017;0(0):.  2017
  125. Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation
    Authors: K Miyata, A Takemoto, S Okumura, M Nishio, N Fujita
    Sci Rep, 2017;7(1):4059.  2017
  126. Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation.
    Authors: Benjamin Y Owusu, Shantasia Thomas, Phanindra Venukadas, Zhenfu Han, James W Janetka, Robert A Galemmo, Lidija Klampfer
    Oncotarget, 2017;0(0):1949-2553.  2017
  127. Dual�Targeting�of�Insulin�Receptor�and�KIT�in�Imatinib-Resistant�Gastrointestinal�Stromal�Tumors
    Authors: W Chen, Y Kuang, HB Qiu, Z Cao, Y Tu, Q Sheng, G Eilers, Q He, HL Li, M Zhu, Y Wang, R Zhang, Y Wu, F Meng, JA Fletcher, WB Ou
    Cancer Res., 2017;0(0):.  2017
  128. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Authors: Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam K, Munoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill R, Roche J, Drabkin H, Haura E
    PLoS ONE, 2016;11(1):e0147344.  2016
  129. Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15
    PLoS ONE, 2016;11(5):e0155561.  2016
  130. Coronary vasculature patterning requires a novel endothelial ErbB2 holoreceptor
    Nat Commun, 2016;7(0):12038.  2016
  131. Activation of EGFR Bypass Signaling by TGF? Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells
    Authors: T Tani, H Yasuda, J Hamamoto, A Kuroda, D Arai, K Ishioka, K Ohgino, M Miyawaki, I Kawada, K Naoki, Y Hayashi, T Betsuyaku, K Soejima
    Mol. Cancer Ther., 2016;15(1):162-71.  2016
  132. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1
    Authors: T Yamaguchi, C Lu, L Ida, K Yanagisawa, J Usukura, J Cheng, N Hotta, Y Shimada, H Isomura, M Suzuki, T Fujimoto, T Takahashi
    Nat Commun, 2016;7(0):10060.  2016
  133. FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases
    Authors: Y Xu, K Wang, Q Yu
    Oncotarget, 2016;7(43):70080-70091.  2016
  134. c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma
    Authors: M Huang, T Liu, P Ma, RA Mitteer, Z Zhang, HJ Kim, E Yeo, D Zhang, P Cai, C Li, L Zhang, B Zhao, L Roccogrand, DM O'Rourke, N Dahmane, Y Gong, C Koumenis, Y Fan
    J Clin Invest, 2016;0(0):.  2016
  135. EphA2 is a functional receptor for the growth factor progranulin
    Authors: Thomas Neill
    J. Cell Biol, 2016;215(5):687-703.  2016
  136. Impaired dynamin 2 function leads to increased AP-1 transcriptional activity through the JNK/c-Jun pathway.
    Authors: Szymanska E, Skowronek A, Miaczynska M
    Cell Signal, 2016;28(1):160-71.  2016
  137. Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the Downregulation of Epidermal Growth Factor Receptor
    Authors: Maurizio Bifulco
    Int. J. Cancer, 2016;0(0):.  2016
  138. Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases
    Authors: G Cassinelli, E Favini, L Dal Bo, M Tortoreto, M De Maglie, G Dagrada, S Pilotti, F Zunino, N Zaffaroni, C Lanzi
    Oncotarget, 2016;7(30):47848-47863.  2016
  139. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.
    Authors: Puzanov I, Lindsay C, Goff L, Sosman J, Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A, Chan E, Evans T
    Clin Cancer Res, 2015;21(4):701-11.  2015
  140. MITF Modulates Therapeutic Resistance through EGFR Signaling.
    Authors: Ji Z, Erin Chen Y, Kumar R, Taylor M, Jenny Njauw C, Miao B, Frederick D, Wargo J, Flaherty K, Jonsson G, Tsao H
    J Invest Dermatol, 2015;135(7):1863-72.  2015
  141. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Authors: Broecker-Preuss M, Muller S, Britten M, Worm K, Kurt Werner S, Mann K, Fuhrer D
    BMC Cancer, 2015;15(0):184.  2015
  142. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
    Authors: Song A, Kim T, Kim D, Kim S, Keam B, Lee S, Heo D
    Clin Cancer Res, 2015;21(10):2379-87.  2015
  143. Artificial human Met agonists based on macrocycle scaffolds.
    Authors: Ito, Kenichir, Sakai, Katsuya, Suzuki, Yoshinor, Ozawa, Naoya, Hatta, Tomohisa, Natsume, Tohru, Matsumoto, Kunio, Suga, Hiroaki
    Nat Commun, 2015;6(0):6373.  2015
  144. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Authors: Cohen N, Zeng S, Seifert A, Kim T, Sorenson E, Greer J, Beckman M, Santamaria-Barria J, Crawley M, Green B, Rossi F, Besmer P, Antonescu C, DeMatteo R
    Cancer Res, 2015;75(10):2061-70.  2015
  145. Biologically active LIL proteins built with minimal chemical diversity.
    Authors: Heim E, Marston J, Federman R, Edwards A, Karabadzhak A, Petti L, Engelman D, DiMaio D
    Proc Natl Acad Sci U S A, 2015;112(34):E4717-25.  2015
  146. LMP1 promotes expression of insulin-like growth factor 1 (IGF1) to selectively activate IGF1 receptor and drive cell proliferation.
    Authors: Tworkoski K, Raab-Traub N
    J Virol, 2015;89(5):2590-602.  2015
  147. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways.
    Authors: Wu, Jia-Ru, Hu, Chi-Tan, You, Ren-In, Ma, Pei-Ling, Pan, Siou-Mei, Lee, Ming-Che, Wu, Wen-Shen
    PLoS ONE, 2015;10(1):e0114495.  2015
  148. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells.
    Authors: Wang, J, Mikse, O, Liao, R G, Li, Y, Tan, L, Janne, P A, Gray, N S, Wong, K-K, Hammerman, P S
    Oncogene, 2015;34(17):2167-77.  2015
  149. Identification of Novel Biomarkers for Metastatic Colorectal Cancer Using Angiogenesis-Antibody Array and Intracellular Signaling Array.
    Authors: Chung S, Dwabe S, Elshimali Y, Sukhija H, Aroh C, Vadgama J
    PLoS ONE, 2015;10(8):e0134948.  2015
  150. Regulation of prostate stromal fibroblasts by the PIM1 protein kinase.
    Authors: Zemskova M, Song J, Cen B, Cerda-Infante J, Montecinos V, Kraft A
    Cell Signal, 2015;27(1):135-46.  2015
  151. Extracellular superoxide dismutase regulates the expression of small gtpase regulatory proteins GEFs, GAPs, and GDI.
    Authors: Laukkanen, Mikko O, Cammarota, Francesc, Esposito, Tiziana, Salvatore, Marco, Castellone, Maria D
    PLoS ONE, 2015;10(3):e0121441.  2015
  152. An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII.
    Authors: Li L, Chakraborty S, Yang C, Hatanpaa K, Cipher D, Puliyappadamba V, Rehman A, Jiwani A, Mickey B, Madden C, Raisanen J, Burma S, Saha D, Wang Z, Pingle S, Kesari S, Boothman D, Habib A
    Oncogene, 2014;33(33):4253-64.  2014
  153. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up.
    Authors: Ugurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pfohler C, Schiller M, Hauschild A, Hein R, Kampgen E, Kellner I, Leverkus M, Becker J, Strobel P, Schadendorf D
    Clin Cancer Res, 2014;20(2):499-510.  2014
  154. MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma.
    Authors: Wang, Lu-Kai, Hsiao, Tzu-Hung, Hong, Tse-Ming, Chen, Hsuan-Yu, Kao, Shih-Han, Wang, Wen-Lung, Yu, Sung-Lia, Lin, Ching-We, Yang, Pan-Chyr
    PLoS ONE, 2014;9(5):e96765.  2014
  155. Transgenic expression of the N525S-tuberin variant in Tsc2 mutant (Eker) rats causes dominant embryonic lethality.
    Authors: Shiono, Masatosh, Kobayashi, Toshiyuk, Takahashi, Riichi, Ueda, Masatsug, Ishioka, Chikashi, Hino, Okio
    Sci Rep, 2014;4(0):5927.  2014
  156. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
    Authors: Montero J, Esparis-Ogando A, Re-Louhau M, Seoane S, Abad M, Calero R, Ocana A, Pandiella A
    Oncogene, 2014;33(2):148-56.  2014
  157. A reactive oxygen species-mediated, self-perpetuating loop persistently activates platelet-derived growth factor receptor alpha.
    Authors: Lei H, Kazlauskas A
    Mol Cell Biol, 2014;34(1):110-22.  2014
  158. Improvement of human keratinocyte migration by a redox active bioelectric dressing.
    Authors: Banerjee J, Das Ghatak P, Roy S, Khanna S, Sequin E, Bellman K, Dickinson B, Suri P, Subramaniam V, Chang C, Sen C
    PLoS ONE, 2014;9(3):e89239.  2014
  159. Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor (EGFR) in cancer cells.
    Authors: Sakanyan V, Angelini M, Le Bechec M, Lecocq M, Benaiteau F, Rousseau B, Gyulkhandanyan A, Gyulkhandanyan L, Loge C, Reiter E, Roussakis C, Fleury F
    Sci Rep, 2014;4(0):3977.  2014
  160. Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis.
    Authors: Calero R, Morchon E, Johnsen J, Serrano R
    PLoS ONE, 2014;9(4):e95628.  2014
  161. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines.
    Authors: Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Xiao M, Li L, Gimotty P, Wilson M, Hayden J, Keeney F, Nathanson K, Herlyn M
    Oncogene, 2014;33(14):1850-61.  2014
  162. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.
    Authors: Imura, Yoshinor, Yasui, Hirohiko, Outani, Hidetats, Wakamatsu, Toru, Hamada, Kenichir, Nakai, Takaaki, Yamada, Shutaro, Myoui, Akira, Araki, Nobuhito, Ueda, Takafumi, Itoh, Kazuyuki, Yoshikawa, Hideki, Naka, Norifumi
    Mol Cancer, 2014;13(0):185.  2014
  163. Comparative receptor tyrosine kinase profiling identifies a novel role for AXL in human stem cell pluripotency.
    Authors: Son M, Seol B, Han Y, Cho Y
    Hum Mol Genet, 2014;23(7):1802-16.  2014
  164. EGFR signaling in the HGG-02 glioblastoma cell line with an unusual loss of EGFR gene copy.
    Authors: Skoda J, Neradil J, Zitterbart K, Sterba J, Veselska R
    Oncol Rep, 2014;31(1):480-7.  2014
  165. Expressed glycosylphosphatidylinositol-anchored horseradish peroxidase identifies co-clustering molecules in individual lipid raft domains.
    Authors: Miyagawa-Yamaguchi, Arisa, Kotani, Norihiro, Honke, Koichi
    PLoS ONE, 2014;9(3):e93054.  2014
  166. Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS.
    Authors: Outani, Hidetats, Tanaka, Takaaki, Wakamatsu, Toru, Imura, Yoshinor, Hamada, Kenichir, Araki, Nobuhito, Itoh, Kazuyuki, Yoshikawa, Hideki, Naka, Norifumi
    BMC Cancer, 2014;14(0):455.  2014
  167. Liver kinase B1 expression promotes phosphatase activity and abrogation of receptor tyrosine kinase phosphorylation in human cancer cells.
    Authors: Okon I, Coughlan K, Zou M
    J Biol Chem, 2014;289(3):1639-48.  2014
  168. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling.
    Authors: Cuenca-Lopez M, Montero J, Morales J, Prat A, Pandiella A, Ocana A
    BMC Cancer, 2014;14(0):302.  2014
  169. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
    Authors: Carlino M, Todd J, Gowrishankar K, Mijatov B, Pupo G, Fung C, Snoyman S, Hersey P, Long G, Kefford R, Rizos H
    Mol Oncol, 2014;8(3):544-54.  2014
  170. Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRbeta aptamer.
    Authors: Camorani S, Esposito C, Rienzo A, Catuogno S, Iaboni M, Condorelli G, de Franciscis V, Cerchia L
    Mol Ther, 2014;22(4):828-41.  2014
  171. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.
    Authors: Drake J, Graham N, Lee J, Stoyanova T, Faltermeier C, Sud S, Titz B, Huang J, Pienta K, Graeber T, Witte O
    Proc Natl Acad Sci U S A, 2013;110(49):E4762-9.  2013
  172. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein.
    Authors: Krzyzaniak M, Zumstein M, Gerez J, Picotti P, Helenius A
    PLoS Pathog, 2013;9(4):e1003309.  2013
  173. Myocilin mediates myelination in the peripheral nervous system through ErbB2/3 signaling.
    Authors: Kwon, Heung Su, Johnson, Thomas V, Joe, Myung Ku, Abu-Asab, Mones, Zhang, Jun, Chan, Chi Chao, Tomarev, Stanisla
    J Biol Chem, 2013;288(37):26357-71.  2013
  174. Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate screen identifies EphA2 as a target for LAR in cell migration.
    Authors: Lee H, Bennett A
    Mol Cell Biol, 2013;33(7):1430-41.  2013
  175. The uremic toxin adsorbent AST-120 abrogates cardiorenal injury following myocardial infarction.
    Authors: Lekawanvijit S, Kumfu S, Wang B, Manabe M, Nishijima F, Kelly D, Krum H, Kompa A
    PLoS ONE, 2013;8(12):e83687.  2013
  176. Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling.
    Authors: Britschgi A, Bill A, Brinkhaus H, Rothwell C, Clay I, Duss S, Rebhan M, Raman P, Guy C, Wetzel K, George E, Popa M, Lilley S, Choudhury H, Gosling M, Wang L, Fitzgerald S, Borawski J, Baffoe J, Labow M, Gaither L, Bentires-Alj M
    Proc Natl Acad Sci U S A, 2013;110(11):E1026-34.  2013
  177. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
    Authors: Davies, Kurtis D, Mahale, Sakshi, Astling, David P, Aisner, Dara L, Le, Anh T, Hinz, Trista K, Vaishnavi, Aria, Bunn, Paul A J, Heasley, Lynn E, Tan, Aik-Choo, Camidge, D Ross, Varella-Garcia, Marileil, Doebele, Robert C
    PLoS ONE, 2013;8(12):e82236.  2013
  178. Insulin/IGF-I signaling pathways enhances tumor cell invasion through bisecting GlcNAc N-glycans modulation. an interplay with E-cadherin.
    Authors: de-Freitas-Junior J, Carvalho S, Dias A, Oliveira P, Cabral J, Seruca R, Oliveira C, Morgado-Diaz J, Reis C, Pinho S
    PLoS ONE, 2013;8(11):e81579.  2013
  179. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.
    Authors: Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL
    Proc. Natl. Acad. Sci. U.S.A., 2012;109(8):2718-23.  2012
  180. Prostaglandin E(2) induces oncostatin M expression in human chronic wound macrophages through Axl receptor tyrosine kinase pathway.
    J. Immunol., 2012;189(5):2563-73.  2012
  181. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.
    Authors: Duncan J, Whittle M, Nakamura K, Abell A, Midland A, Zawistowski J, Johnson N, Granger D, Jordan N, Darr D, Usary J, Kuan P, Smalley D, Major B, He X, Hoadley K, Zhou B, Sharpless N, Perou C, Kim W, Gomez S, Chen X, Jin J, Frye S, Earp H, Graves L, Johnson G
    Cell, 2012;149(2):307-21.  2012
  182. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
    Authors: Joshi, Avadhut, Loilome, Watchari, Siu, I-Mei, Tyler, Betty, Gallia, Gary L, Riggins, Gregory
    PLoS ONE, 2012;7(10):e44372.  2012
  183. Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma.
    Authors: Purushothaman, Anurag, Babitz, Stephen, Sanderson, Ralph D
    J Biol Chem, 2012;287(49):41288-96.  2012
  184. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
    Authors: Oliveras-Ferraros C, Cufi S, Queralt B, Vazquez-Martin A, Martin-Castillo B, de Llorens R, Bosch-Barrera J, Brunet J, Menendez JA
    Br. J. Cancer, 2012;106(8):1406-14.  2012
  185. PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma.
    Authors: Ho A, Vasudeva S, Lae M, Saito T, Barbashina V, Antonescu C, Ladanyi M, Schwartz G
    Cancer Res, 2012;72(17):4515-25.  2012
  186. Fibroblast Growth Factor Receptor 3 (FGFR3) Associated with the CD20 Antigen Regulates the Rituximab-induced Proliferation Inhibition in B-cell Lymphoma Cells.
    Authors: Kotani N, Ishiura Y, Yamashita R, Ohnishi T, Honke K
    J Biol Chem, 2012;287(44):37109-18.  2012
  187. MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway.
    Authors: Lorenzon E, Colladel R, Andreuzzi E, Marastoni S, Todaro F, Schiappacassi M, Ligresti G, Colombatti A, Mongiat M
    Oncogene, 2012;31(26):3136-47.  2012
  188. Inhibition of platelet-derived growth factor receptor signaling regulates Oct4 and Nanog expression, cell shape, and mesenchymal stem cell potency.
    Authors: Ball SG, Shuttleworth A, Kielty CM
    Stem Cells, 2012;30(3):548-60.  2012
  189. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.
    Authors: Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M, Eschrich S, Altiok S, Koomen J, Haura E
    Cancer Res, 2012;72(10):2501-11.  2012
  190. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
    Authors: Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H
    J. Invest. Dermatol., 2012;132(7):1850-9.  2012
  191. Survival of cancer stem cells under hypoxia and serum depletion via decrease in PP2A activity and activation of p38-MAPKAPK2-Hsp27.
    Authors: Lin, Shih-Pei, Lee, Yi-Ting, Wang, Jir-You, Miller, Stephani, Chiou, Shih-Hwa, Hung, Mien-Chi, Hung, Shih-Chi
    PLoS ONE, 2012;7(11):e49605.  2012
  192. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
    Clin. Cancer Res., 2012;18(17):4570-9.  2012
  193. A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma.
    Authors: Godshalk SE, Paranjape T, Nallur S, Speed W, Chan E, Molinaro AM, Bacchiocchi A, Hoyt K, Tworkoski K, Stern DF, Sznol M, Ariyan S, Lazova R, Halaban R, Kidd KK, Weidhaas JB, Slack FJ
    Oncogene, 2011;30(13):1542-50.  2011
  194. Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion.
    Authors: Henriksson ML, Edin S, Dahlin AM, Oldenborg PA, Oberg Ã…, Van Guelpen B, Rutegard J, Stenling R, Palmqvist R
    Am. J. Pathol., 2011;178(3):1387-94.  2011
  195. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification.
    Authors: Tanizaki J, Okamoto I, Sakai K
    Br. J. Cancer, 2011;105(6):807-13.  2011
  196. Somatic cell plasticity and Niemann-Pick type C2 protein: fibroblast activation.
    Authors: Csepeggi C, Jiang M, Kojima F
    J. Biol. Chem., 2011;286(3):2078-87.  2011
  197. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
    Authors: Poulikakos PI, Persaud Y, Janakiraman M
    Nature, 2011;480(7377):387-90.  2011
  198. Sesamin induces autophagy in colon cancer cells by reducing tyrosine phosphorylation of EphA1 and EphB2.
    Authors: Tanabe H, Kuribayashi K, Tsuji N
    Int. J. Oncol., 2011;39(1):33-40.  2011
  199. Tyrosine phosphorylation profiling in FGF-2 stimulated human embryonic stem cells.
    Authors: Ding VM, Boersema PJ, Foong LY
    PLoS ONE, 2011;6(3):e17538.  2011
  200. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
    Authors: Jiao Y, Ou W, Meng F
    Mol. Cancer, 2011;10(0):125.  2011
  201. The MARCH family E3 ubiquitin ligase K5 alters monocyte metabolism and proliferation through receptor tyrosine kinase modulation.
    Authors: Karki R, Lang SM, Means RE
    PLoS Pathog., 2011;7(4):e1001331.  2011
  202. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.
    Authors: Carrasco-Garcia E, Saceda M, Grasso S, Rocamora-Reverte L, Conde M, Gomez-Martinez A, Garcia-Morales P, Ferragut JA, Martinez-Lacaci I
    Exp. Cell Res., 2011;317(10):1476-89.  2011
  203. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.
    Authors: Ou WB, Hubert C, Corson JM, Bueno R, Flynn DL, Sugarbaker DJ, Fletcher JA
    Neoplasia, 2011;13(1):12-22.  2011
  204. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.
    Authors: Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoel M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF
    Nat. Med., 2011;17(5):589-95.  2011
  205. 18FDG-PET Predicts Pharmacodynamic Response to OSI-906, a Dual IGF-1R/IR Inhibitor, in Preclinical Mouse Models of Lung Cancer.
    Authors: McKinley ET, Bugaj JE, Zhao P, Guleryuz S, Mantis C, Gokhale PC, Wild R, Manning HC
    Clin. Cancer Res., 2011;17(10):3332-40.  2011
  206. Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane.
    Authors: Tang WH, Stitham J, Gleim S, Di Febbo C, Porreca E, Fava C, Tacconelli S, Capone M, Evangelista V, Levantesi G, Wen L, Martin K, Minuz P, Rade J, Patrignani P, Hwa J
    J. Clin. Invest., 2011;121(11):4462-76.  2011
  207. Functional mapping of receptor tyrosine kinases in myxoid liposarcoma.
    Authors: Negri T, Virdis E, Brich S, Bozzi F, Tamborini E, Tarantino E, Jocolle G, Cassinelli G, Grosso F, Sanfilippo R, Casalini P, Greco A, Pierotti MA, Pilotti S
    Clin. Cancer Res., 2010;16(14):3581-93.  2010
  208. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
    Authors: Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, Maehara Y, Yatabe Y, Mitsudomi T
    Clin. Cancer Res., 2010;16(22):5489-98.  2010
  209. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
    Authors: Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M
    Cancer Cell, 2010;18(6):683-95.  2010
  210. VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27(KIP1) via paracrine mechanisms.
    Authors: Roorda BD, Ter Elst A, Scherpen FJ, Meeuwsen-de Boer TG, Kamps WA, de Bont ES
    Eur. J. Cancer, 2010;46(5):974-82.  2010
  211. Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction.
    Authors: Cook SA, Varela-Carver A, Mongillo M
    Eur. Heart J., 2010;31(1):100-11.  2010
  212. Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells.
    Authors: Kang HG, Jenabi JM, Liu XF, Reynolds CP, Triche TJ, Sorensen PH
    Mol. Cancer Ther., 2010;9(5):1396-407.  2010
  213. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.
    Authors: Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, Messina A, Pastorino U, Pierotti MA, Casali PG, Pilotti S
    Mol. Cancer Ther., 2010;9(5):1286-97.  2010
  214. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.
    Authors: Strobel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou-Strauss A, Strauss L, Sauer C, Mayer F, Hohenberger P, Marx A
    Br. J. Cancer, 2010;103(2):196-200.  2010
  215. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch.
    Authors: Ding W, Knox TR, Tschumper RC
    Blood, 2010;116(16):2984-93.  2010
  216. Coactivated platelet-derived growth factor receptor alpha and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.
    Authors: Dewaele B, Floris G, Finalet-Ferreiro J, Fletcher CD, Coindre JM, Guillou L, Hogendoorn PC, Wozniak A, Vanspauwen V, Schoffski P, Marynen P, Vandenberghe P, Sciot R, Debiec-Rychter M
    Cancer Res., 2010;70(18):7304-14.  2010
  217. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.
    Authors: Flanigan SA, Pitts TM, Eckhardt SG, Tentler JJ, Tan AC, Thorburn A, Leong S
    Clin. Cancer Res., 2010;16(22):5436-46.  2010
  218. Somatic cell plasticity and Niemann-pick type C2 protein: adipocyte differentiation and function.
    Authors: Csepeggi C, Jiang M, Frolov A
    J. Biol. Chem., 2010;285(39):30347-54.  2010
  219. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
    Authors: Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Perez-Martinez MC, Cufi S, Del Barco S, Bernado L, Brunet J, Lopez-Bonet E, Menendez JA
    Int. J. Oncol., 2010;37(3):669-78.  2010
  220. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Authors: Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS
    Nature, 2010;468(7326):973-7.  2010
  221. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
    Authors: Yoon YK, Kim HP, Han SW, Hur HS, Oh do Y, Im SA, Bang YJ, Kim TY
    Mol. Cancer Ther., 2009;8(9):2526-36.  2009
  222. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells.
    Authors: Agarwal S, Zerillo C, Kolmakova J, Christensen JG, Harris LN, Rimm DL, Digiovanna MP, Stern DF
    Br. J. Cancer, 2009;100(6):941-9.  2009
  223. Human cancers converge at the HIF-2alpha oncogenic axis.
    Authors: Franovic A, Holterman CE, Payette J, Lee S
    Proc. Natl. Acad. Sci. U.S.A., 2009;106(50):21306-11.  2009
  224. A complex role for FGF-2 in self-renewal, survival, and adhesion of human embryonic stem cells.
    Authors: Eiselleova L, Matulka K, Kriz V, Kunova M, Schmidtova Z, Neradil J, Tichy B, Dvorakova D, Pospisilova S, Hampl A, Dvorak P
    Stem Cells, 2009;27(8):1847-57.  2009
  225. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
    Authors: Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY, Reis-Filho JS, Stavale JN, Al-Sarraj S, Reis RM, Vassal G, Pearson AD, Hargrave D, Ellison DW, Workman P, Jones C
    Clin. Cancer Res., 2009;15(18):5753-61.  2009
  226. Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response.
    Authors: Marston E, Weston V, Jesson J, Maina E, McConville C, Agathanggelou A, Skowronska A, Mapp K, Sameith K, Powell JE, Lawson S, Kearns P, Falciani F, Taylor M, Stankovic T
    Blood, 2009;113(1):117-26.  2009
  227. A redox-silent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cells.
    Authors: Kashiwagi K, Virgona N, Harada K, Kido W, Yano Y, Ando A, Hagiwara K, Yano T
    Life Sci., 2009;84(19):650-6.  2009
  228. Decorin is a novel antagonistic ligand of the Met receptor.
    Authors: Goldoni S, Humphries A, Nystrom A, Sattar S, Owens RT, McQuillan DJ, Ireton K, Iozzo RV
    J. Cell Biol., 2009;185(4):743-54.  2009
  229. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
    Authors: Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, Ueda Y, Yatabe Y, Ito M, Horio Y, Hida T, Sekido Y
    Carcinogenesis, 2009;30(7):1097-105.  2009
  230. Response to sunitinib malate in advanced alveolar soft part sarcoma.
    Authors: Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A, Pierotti MA, Casali PG, Pilotti S
    Clin. Cancer Res., 2009;15(3):1096-104.  2009
  231. Transactivation of RON receptor tyrosine kinase by interaction with PDGF receptor beta during steady-state growth of human mesangial cells.
    Authors: Kobayashi T, Furukawa Y, Kikuchi J, Ito C, Miyata Y, Muto S, Tanaka A, Kusano E
    Kidney Int., 2009;75(11):1173-83.  2009
  232. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.
    Authors: Eckstein N, Servan K, Hildebrandt B, Politz A, von Jonquieres G, Wolf-Kummeth S, Napierski I, Hamacher A, Kassack MU, Budczies J, Beier M, Dietel M, Royer-Pokora B, Denkert C, Royer HD
    Cancer Res., 2009;69(7):2996-3003.  2009
  233. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.
    Authors: Mueller KL, Hunter LA, Ethier SP, Boerner JL
    Cancer Res., 2008;68(9):3314-22.  2008
  234. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
    Authors: Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS
    Cancer Res., 2008;68(20):8322-32.  2008
  235. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
    Authors: Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C, Lutterbach B
    Cancer Res., 2008;68(7):2340-8.  2008
  236. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.
    Authors: Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, Lowell AM, Minami Y, McNamara K, Perera SA, Zaghlul S, Thomas RK, Greulich H, Kobayashi S, Chirieac LR, Padera RF, Kubo S, Takahashi M, Tenen DG, Meyerson M, Wong KK, Shapiro GI
    Cancer Res., 2008;68(14):5827-38.  2008
  237. Molecular characterization of pediatric gastrointestinal stromal tumors.
    Authors: Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, Maki RG, DeMatteo RP, Besmer P, Antonescu CR
    Clin. Cancer Res., 2008;14(10):3204-15.  2008
  238. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.
    Authors: Yu L, Saile K, Swartz CD, He H, Zheng X, Kissling GE, Di X, Lucas S, Robboy SJ, Dixon D
    Mol. Med., 2008;14(5):264-75.  2008
  239. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
    Authors: Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Janne PA
    Clin. Cancer Res., 2008;14(13):4275-83.  2008
  240. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase.
    Authors: Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ, Sorensen PH
    Cancer Res., 2007;67(7):3094-105.  2007
  241. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
    Authors: Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA
    Science, 2007;316(5827):1039-43.  2007
  242. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors.
    Authors: Ball SG, Shuttleworth CA, Kielty CM
    J. Cell Biol., 2007;177(3):489-500.  2007
  243. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
    Authors: Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA
    Science, 2007;318(5848):287-90.  2007
  244. Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling.
    Authors: Wang L, Schulz TC, Sherrer ES, Dauphin DS, Shin S, Nelson AM, Ware CB, Zhan M, Song CZ, Chen X, Brimble SN, McLean A, Galeano MJ, Uhl EW, D'Amour KA, Chesnut JD, Rao MS, Blau CA, Robins AJ
    Blood, 2007;110(12):4111-9.  2007
  245. Fibulin-5 binds human smooth-muscle cells through alpha5beta1 and alpha4beta1 integrins, but does not support receptor activation.
    Authors: Lomas AC, Mellody KT, Freeman LJ, Bax DV, Shuttleworth CA, Kielty CM
    Biochem. J., 2007;405(3):417-28.  2007
  246. Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration.
    Authors: Fujikawa T, Shiraha H, Ueda N, Takaoka N, Nakanishi Y, Matsuo N, Tanaka S, Nishina S, Suzuki M, Takaki A, Sakaguchi K, Shiratori Y
    J. Biol. Chem., 2007;282(12):8741-8.  2007
  247. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells.
    Authors: Eckstein N, Servan K, Girard L, Cai D, von Jonquieres G, Jaehde U, Kassack MU, Gazdar AF, Minna JD, Royer HD
    J. Biol. Chem., 2007;283(2):739-50.  2007
  248. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
    Authors: Menendez JA, Mehmi I, Lupu R
    J. Clin. Oncol., 2006;24(23):3735-46.  2006
  249. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase.
    Authors: Cohen EE, Lingen MW, Zhu B, Zhu H, Straza MW, Pierce C, Martin LE, Rosner MR
    Cancer Res., 2006;66(12):6296-303.  2006


  1. What are the phosphorylation site(s) of the 49 different tyrosine residues on the RTKs?

    • This kit uses a pan anti-phospho-tyrosine antibody as the detection antibody, which means it is capable of detecting phosphorylation at any available tyrosine. It is not designed to be specific for one phosphorylation site on each molecule. For instance, PDGF R alpha has multiple sites of tyrosine phosphorylation (see the “PTM/Processing” section of for a list of the currently identified sites). 

  2. Can the Human Phospho-RTK Array be used for measuring the relative levels of total RTKs present in a sample?

    • No. Although the array kit uses capture antibodies that recognize both phosphorylated and unphosphorylated RTKs, the detection antibody is a pan anti-phospho-tyrosine antibody which only detects phosphorylated tyrosines on activated RTKs.

  3. To confirm positive signal for an RTK by IP-Western blot, are the capture antibodies from the Human Phospho-RTK Array Kit offered separately?

    • The identities of the capture antibodies on the Human Phospho-RTK Array are considered proprietary. However, to help investigators confirm their array results, Bio-Techne offers antibodies for each RTK detectable in the array kit. These antibodies are validated for Western blot and can be found in our catalog. A pan anti-phospho-tyrosine-HRP detection antibody is also available (Catalog # HAM1676).

View all Proteome Profiler Antibody Array FAQs

Reviews for Proteome Profiler Human Phospho-RTK Array Kit

Average Rating: 5 (Based on 7 Reviews)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used Proteome Profiler Human Phospho-RTK Array Kit?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

Proteome Profiler Human Phospho-RTK Array Kit
By 帆 张 on 08/31/2021

Great, excellent, can't wait to start my experiences right away.

Proteome Profiler Human Phospho-RTK Array Kit
By Anonymous on 07/15/2021

Purchased to screen changes induced by RTK inhibitors of cancer cell lines. Easy protocol, good clear results which could be independently validated by western blot. The only issue is that R&D are unable to supply information regarding the phospho-site detected, the antibody used in the array or the receptor chain recognised, so you just have to make an educated guess as to which antibody is most appropriate for an independent validation by western blotting etc. Excellent as an initial screen though.

Proteome Profiler Human Phospho-RTK Array Kit
By Anonymous on 11/18/2019

I would recommend to my colleagues, nicely performed. (for image acquiring, I used ImageQuant LAS 4000)

Proteome Profiler Human Phospho-RTK Array Kit
By Anonymous on 03/13/2019

Proteome Profiler Human Phospho-RTK Array Kit
By Anonymous on 10/29/2018

Proteome Profiler Human Phospho-RTK Array Kit
By Jiawan Wang on 08/28/2018

The kit is excellent for p-RTK array in human cell lines. I recommended it to my colleague.

Proteome Profiler Human Phospho-RTK Array Kit
By Adam Guess on 10/20/2017